10th KAPAL On-Air Webinar (2022 KAPAL-KHIDI Webinar Series #1) (April 7, 2021, 8:00 – 9:30 PM EST)

2022 KAPAL–KHIDI Bio & Health Webinar Series는 한미생명과학인 협회 (KAPAL)와 KHIDI 미국지사 웨비나 시리즈입니다.

Topic Title: US R&D Tax Credit & Corporate Tax

o “US R&D Tax Credit Introduction”

Christina Ahn, CPA, R&D Credit Specialist, Ardius (acquired by Gusto)

“US Corporate Tax Filing Requirements and Transfer Pricing Issues”

Alex Koo, Tax Partner, KPMG LLP / Shawn Kim, Managing Director, KPMG LLP

About the presenter:

Christina Ahn, CPA

R&D Credit Specialist, Ardius (acquired by Gusto)

Co-founder and CEO, Pinecone41

Pinecone41 is a Fintech startup that specializes in R&D Tax Credit services and provide technology startups accurate and beneficial tax insights that can be used to fuel growth.

Top Skills

Financial Analysis, Data Analysis, Corporate Tax

Experience

Ardius (acquired by Gusto, R&D Credit Specialist), Pinecone41 (CEO), KPMG (Tax Manager), Deloitte Tax LLP (Senior Tax Consultant), Mah & Associates (Staff Accountant)

Alex Koo

Tax Partner, KPMG LLP

Alex is a Tax Partner in KPMG’s Los Angeles Federal Tax Services, Korean practice. Before joining KPMG, Alex started his career in the tax department of Deloitte Korea and performed various tax projects until he was seconded to the US office. He has more than 20 years of experience in U.S. and Korea tax consulting, income tax compliance and income tax provision.

Alex is responsible for a broad range of U.S. multi-national and foreign-owned clients doing business as single entities or joint ventures, and has extensive experience with a wide range of tax matters relating to multi-national businesses. Alex’s current and past clients include leaders in the industrial production industries and high-technology, media, and telecommunication industries.

Alex has provided tax compliance services for various engagements in size from private to multi-national public companies in the U.S. and Korea and has extensive experience in defending corporations against tax examinations by Federal and state tax authorities.

Alex also has provided tax consulting services related to merger & acquisition transactions, business transfer transactions, cross border transactions and various tax due diligence services.

Alex has strong tax technical skills and tax provision skills with extensive experience in ASC 740 and ASC 718-10 for multinational and private companies.

Shawn Kim

Managing Director, KPMG LLP

Sanghoon has over 18 years of experience in dealing with audit, tax and transfer pricing matters for multinationals operating in different industries, from manufacturing and distribution sectors to the financial industry.

Sanghoon manages tax planning, audit defense and documentation projects for significant and complex intercompany transactions, covering tangible goods, complex services, intellectual property and financing structures. He deals with tax authorities on behalf of taxpayers with respect to transfer pricing audit defense and Advance Pricing Arrangements.

Work Experience

• Dealt with tax authorities related to tax audit, tax appeal, advance pricing agreement (APA), and mutual agreement procedure (MAP)

• Assisted companies in preparing worldwide transfer pricing policies

• Assisted companies in preparing FIN 48 analyses

• Prepared transfer pricing planning study and contemporaneous transfer pricing documentations

• Prepared management service fee documentation

• Performed intellectual property valuation analyses

• Performed royalty analysis products, especially in automobile parts industry

***** Notice *****

* Please note that the webinar talk will be presented in ENGLISH language. But Q&A session will be conducted in both English and Korean.

* 이번 세미나는 Maryland 주정부 관계자 분들을 포함하여 영어권 참석자 분들이 있어, 강의는 영어로 진행될 예정입니다. 참고로 질의 응답은 영어와 한국어 모두 가능함을 안내 드립니다.

9th KAPAL On-Air Webinar (2021 KAPAL-KHIDI Webinar Series #3) (November 4, 2021, 9:00 – 10:30 PM EST)

2021 KAPAL–KHIDI Bio & Health Webinar Series는 한미생명과학인 협회 (KAPAL)와 KHIDI 미국지사 웨비나 시리즈입니다.

Topic Title: Clinical Development ‘R’ us

Clinical development has been the significant challenge for drug developers due to a low likelihood of success (e.g., 9.6% from Phase I for all developmental candidates*). Regulatory sciences and strategies become increasingly critical pillars in building clinical development plan for any successful new drug development.

In this presentation, roles of regulatory sciences and strategies in the clinical development will be elaborated.

* Clinical development success rate 2006-2015, BIO Industry Analysis

About the presenter:

Sang Mok Chung, Ph.D.

Vice President of Regulatory Affairs

LG Chem Life Sciences Innovation Center, Cambridge, MA

Dr. Chung has dedicated his professional development at building expertise in regulatory science* of drug development. Dr. Chung has extensively reviewed regulatory submissions such as Investigational New Drug, New Drug Application or Biologic License Application from clinical pharmacology perspectives as part of multidisciplinary team. Dr. Chung’s review experiences cover conventional small molecules, peptides, oligonucleotides, biologics and biosimilars. Dr. Chung has therapeutic backgrounds in the areas of diabetes, lipid disorders, obesity and endocrinology (e.g., growth hormone deficiency, Cushing’s disease, or thyroid hormone) with further expansion in many other diseases (e.g., pulmonary and rheumatology), which can indicate for conventional or rare diseases. Dr. Chung has actively participated in regulatory researches as PI or co-PI, and presenting those results at scientific meetings. Dr. Chung has given lectures related the clinical development to colleges and universities.

Dr. Chung earned Ph.D. in Pharmacokinetics, College of Pharmacy, University of Illinois at Chicago.

* Please note that the webinar talk will be presented in KOREAN language.

https://bit.ly/2ZgKgS7

한미 첨단재생의료 협력 확대를 위한 바이오 산업 포럼 – Oct 14, 2021 (Thr) 18:30 PM (EST)

<한-미 첨단 재생의료 협력 확대를 위한 바이오산업 포럼>

미국(동부) 21.10.14(목) 18:30-22:00 (온라인 생중계는 동부 시간 기준 19:20분 부터)

한국        21.10.15(금) 08:20-11:00

온라인 RSVP : https://forms.gle/J65f48LzkJPYthJj7

오프라인 RSVP: https://forms.gle/h1PJ2Bbh4YHs8Ggu6

행사 관련 보도기사 자료: http://www.hitnews.co.kr/news/articleView.html?idxno=36346

보다 자세한 사항은 행사 포스터 및 보도 기사를 참조해 주시기 바랍니다.

Faculty Job Search in the USA

2002년에 KOLIS회장을 하신 최두섭 교수님(Mayo Clinic)께서 10월 11일 서부시간 오후 5시에 AKN (Association of Korean Neuroscientist, https://akneuro.org)에서 “Faculty Job Search in the USA”라는 제목으로 발표를 하신다고 합니다. Neuroscience뿐만 아니라 다른 분야 분들께도 도움이 될만한 내용일 듯하니 관심있는 분들의 많은 참여 부탁드립니다. 

패널분들 이외에도 30분정도 faculty가 꾸준히 참석하는 모임이라고 하니, 미국에서 자리 잡기를 희망하시는 회원분들은 한번 참석하셔서 좋은 기회를 잡으시길 바랍니다. 

강정민 올림 

#KOLIS 홈페이지: https://www.kolis.org

#KOLIS 인스타그램 페이지: https://www.instagram.com/kolis_official/

#KOLIS 페이스북 페이지: https://www.facebook.com/groups/kolis.us/

#KOLIS 회원가입: https://forms.gle/yTPQ8ymVqzjQmSr48

KWiSE Forum 4: September 30, 8:30 PM EST (October 1, 9:30 AM KST)

KWiSE (Korean-American Women in Science and Engineering)의 NIH지부 (회장, 김동연 박사)와 Washington DC 지부 (회장, Jinyoung Barnaby 박사) 에서 Korea Foundation의 후원으로 COVID-19을 주제로 온라인으로 한미 공동 포럼을 주최하고 있습니다. 이번 네번째 포럼은 한국시간으로10월 1일 오전 9시반부터 11시까지 진행될 예정입니다.  (미국동부시간 9월 30일 저녁 8:30-10시). 포럼의 주제는  “Monoclonal Antibodies as Therapeutics against SARS-CoV-2: From Development to Regulatory Approval” 입니다.

백신이 이미 개발되어 일반인에게 보급되고 있는 시점이지만 백신 접종후에도 시간이 경과하면서 점차 재감염의 가능성이 높아지는 지금의 상황을 고려할때 항체를 이용한 치료제 개발은 매우 시급하고 적절한 문제가 아닐 수 없습니다. 그러한 면에서 이번 포럼은 과학계를 포함하여 일반인에게도 어필하는 주제라고 생각합니다.

이번 포럼의 연사로는 셀트리온의 부사장님인 이수영 박사님과 미국 식품의약청 (FDA) 에서 team leader로 재직하시는 최수영 박사님 두분을 초청하였습니다. 이수영 박사님은 “Neutralizing Effect of CT-P59 Against SARS-CoV-2 Variants” 라는 주제로,  그리고 최수영 박사님은 “Monoclonal Antibodies Targeting SARS-CoV-2”라는 주제로 심도있고 유익한 강연을 해주실 예정입니다.

이번 포럼은 미국 FDA에 계시는 신양미 박사님이 좌장을 맡아 주시고, 미국 국립보건연구원(NIH) 에서 근무하시는 지영미 박사님의 사회로 진행될 예정입니다. 더 자세한 내용을 보시려면 첨부한 포럼 포스터와 프로그램을 참고하시기 바랍니다.

아래 링크를 통해 등록하시면 무료로 참여하실 수 있으니 많은 성원 부탁드립니다. 아울러 주위에 널리 알려주시면 대단히 감사하겠습니다.

등록링크: http:bit.ly/kwiseforum4